Phase 1b/2a study in cystic fibrosis remains on track for full enrollment by end of 2025 following positive interim analysis announced in JuneCompany closes upsized Series A funding tranche to accelerate pipeline activities COLUMBUS, Ohio–(BUSINESS…
January 28, 2025 08:00 AM Eastern Standard Time COLUMBUS, Ohio–(BUSINESS WIRE)–Clarametyx Biosciences Inc. (“Clarametyx”), a clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, and Kineticos Life Sciences (“Kineticos”),…
According to filings with the U.S. Securities and Exchange Commission, Clarametyx Biosciences is raising up to $33,124,959.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, David Richards played a…
Newly established relationship with Cystic Fibrosis Foundation enables clinical studies targeting cystic fibrosis-associated infections January 05, 2024 10:06 AM Eastern Standard Time COLUMBUS, Ohio–(BUSINESS WIRE)–Clarametyx Biosciences Inc. (“Clarametyx”), a clinical stage company developing targeted, immune-enabling…